Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

July 15, 2022

Study Completion Date

September 20, 2022

Conditions
Small-cell Lung CancerBrain Metastases
Interventions
DRUG

Carboplatin

Carboplatin 5-6 mg/mL/min AUC will be delivered over 30 - 60 minutes intravenously on Day 1 of each 21 day Cycle after completion of atezolizumab. For 4 cycles.

DRUG

Etoposide

Etoposide 80-100 mg/m2 will be delivered over 60 minutes intravenously on Days 1-3 of each 21 day Cycle after completion of carboplatin (Day 1 only). For 4 cycles.

DRUG

Atezolizumab

Atezolizumab 1200 mg will be delivered over 60 (± 15) minutes intravenously on Day 1 of each 21 day Cycle for 4 cycles then continue as monotherapy maintenance with the same schedule.

Trial Locations (6)

27710

Duke Cancer Institute, Durham

46016

St. Vincent Anderson Regional Hospital, Anderson

60612

University of Illinois Cancer Center, Chicago

68114

Nebraska Methodist Hospital, Omaha

91010

City of Hope, Duarte

07922

Summit Health, Berkeley Heights

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Duke University

OTHER

lead

Jeffrey Clarke

OTHER